France completes Lovenox recall
This article was originally published in Scrip
All packs of Sanofi-Aventis's Lovenox (enoxaparin) that were distributed before May have now been removed from the French market, the regulator Afssaps says. The low-molecular weight heparin (LMWH) product was caught up in a worldwide contamination scare earlier this year, but a shortage of suitable replacements led the agency to recommend a phased withdrawal of products it deemed low-risk (Scrip Online, April 25th, 2008).
You may also be interested in...
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.